Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462145 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
A NA study of Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation, sponsored by Kardium.
- Active
- Registry status
- NA
- Development phase
- 549
- Enrollment target
- 18
- Study locations
NCT05462145: Active NA study of Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation, sponsored by Kardium.
NCT05462145 is a NA study of Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation that is active but no longer recruiting, run by Kardium. The registered enrollment target is 549 participants, below the 836-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (34% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462145, a NA study of Paroxysmal Atrial Fibrillation and Persistent Atrial Fibrillation, is active but no longer recruiting, sponsored by Kardium.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 549 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
Primary Outcome
Number of subjects with freedom from documented atrial fibrillation, atrial flutter, and atrial tachycardia (AF/AFL/AT) 12 months post-procedure.
Conditions Studied
Interventions
- DEVICE Globe Pulsed Field System
Study Locations (18)
Other
- Motol and Homolka University Hospital - Prague
- Heart and Diabetes Center NRW - Bad Oeynhausen
- Charité Campus Virchow Clinic - Berlin
- Westpfalz-Klinikum GmbH Kaiserslautern - Kaiserslautern
Florida
- St. Vincent's Medical Center - Jacksonville
- Mercy Hospital - Miami
Pennsylvania
- Doylestown Hospital - Doylestown
- Hospital of the University of Pennsylvania - Philadelphia
Alabama
- Grandview Medical Center - Birmingham
Arkansas
- St. Bernards Medical Center - Jonesboro
California
- Sutter Health - California Pacific Medical Center - San Francisco
Maryland
- Johns Hopkins - Baltimore
Michigan
- Beaumont Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 549 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT05462145 still lists
NCT05462145 is an interventional study that assigns participants to a tested intervention. The registered 549 participants enrollment target is mid-sized for trials with a published cap, below the 836-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (34% lower).
The record links to 2 conditions, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Globe Pulsed Field System is the first listed.
NCT05462145 lists 18 locations in 13 states (Other, Florida, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05462145 about?
NCT05462145 is a clinical study titled "Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation". This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
What is the current status of trial NCT05462145?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 549 participants. The study started on 2023-03-09. Estimated completion is 2026-09.
What conditions does trial NCT05462145 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation.
What interventions are being tested in trial NCT05462145?
The interventions under investigation include: Globe Pulsed Field System (DEVICE).
Who is sponsoring clinical trial NCT05462145?
This trial is sponsored by Kardium, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462145 being conducted?
This trial has 18 study locations across Alabama, Arkansas, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05462145's enrollment target sits among peer trials
549 3rd of 24 higher than 22 of 24 other Paroxysmal Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
POLARx Post Approval Study (POLARx PAS)
RECRUITING · NA
-
Treatment of PAF With the Synaptic System
ACTIVE NOT RECRUITING · NA
-
Meditation and Education That is Nurse Delivered for Symptom Management in Paroxysmal Atrial Fibrillation (PAF)
ACTIVE NOT RECRUITING · NA
-
TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI